Free Trial
NASDAQ:FNCH

Finch Therapeutics Group (FNCH) Stock Price, News & Analysis

Finch Therapeutics Group logo
$14.06 -0.24 (-1.70%)
As of 03/28/2025 02:49 PM Eastern

About Finch Therapeutics Group Stock (NASDAQ:FNCH)

Key Stats

Today's Range
$13.75
$14.30
50-Day Range
$10.95
$15.80
52-Week Range
$0.80
$15.85
Volume
1,352 shs
Average Volume
2,260 shs
Market Capitalization
$22.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Remove Ads
Receive FNCH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter.

FNCH Stock News Headlines

Arquitos Capital Management Q4 2024 Commentary
New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
Finch Therapeutics announces Nasdaq delisting, SEC deregistration
Finch Therapeutics Group to Delist from Nasdaq
See More Headlines

FNCH Stock Analysis - Frequently Asked Questions

Finch Therapeutics Group's stock was trading at $11.30 at the start of the year. Since then, FNCH stock has increased by 24.4% and is now trading at $14.0568.
View the best growth stocks for 2025 here
.

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($6.30) earnings per share for the quarter, topping analysts' consensus estimates of ($12.60) by $6.30. The firm had revenue of $11.34 million for the quarter.

Finch Therapeutics Group shares reverse split on Monday, June 12th 2023. The 1-30 reverse split was announced on Monday, June 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Finch Therapeutics Group (FNCH) raised $101 million in an IPO on Friday, March 19th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO.

Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Finch Therapeutics Group investors own include CNS Pharmaceuticals (CNSP), Faraday Future Intelligent Electric (FFIE), Allarity Therapeutics (ALLR), Aridis Pharmaceuticals (ARDS), Meta Platforms (META), NVIDIA (NVDA) and Altamira Therapeutics (CYTO).

Company Calendar

Last Earnings
11/10/2021
Today
3/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:FNCH
Fax
N/A
Employees
190
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-74,750,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$110,000.00
Price / Cash Flow
N/A
Book Value
$14.25 per share
Price / Book
0.99

Miscellaneous

Free Float
885,000
Market Cap
$22.58 million
Optionable
No Data
Beta
1.21
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:FNCH) was last updated on 3/30/2025 by MarketBeat.com Staff
From Our Partners